What is a Safety Data Exchange Agreement (SDEA)?
Introduction
Pharmacovigilance obligations rarely sit within a single organisation. Modern medicinal products are commonly developed, licensed, distributed and marketed through complex networks involving marketing authorisation holders, licensors, licensees, distributors, contract research organisations, local affiliates and specialised pharmacovigilance service providers.
Safety information may therefore originate in multiple organisations before reaching the party ultimately responsible for regulatory reporting. A Safety Data Exchange Agreement (SDEA) provides the documented framework governing how safety information is exchanged between those parties.
Although SDEAs are contractual documents, their significance extends beyond legal compliance. They are an important component of pharmacovigilance governance because they define how critical safety information moves through the wider pharmacovigilance system. Deficiencies in these arrangements can directly affect adverse event reporting, signal detection, regulatory submissions and inspection readiness.
For Qualified Persons Responsible for Pharmacovigilance (QPPVs), understanding SDEAs is essential because effective oversight of the pharmacovigilance system depends on confidence that safety information received by external partners is transferred accurately, completely and within required timelines.
Why Safety Data Exchange Agreements Exist
The primary purpose of an SDEA is to ensure that pharmacovigilance responsibilities are clearly defined whenever more than one organisation is involved in activities that may generate, receive or process safety information.
Without documented responsibilities, organisations face several risks:
- Delayed adverse event reporting
- Duplicate submissions
- Missing follow-up activities
- Inconsistent regulatory communications
- Incomplete signal evaluation
- Unclear accountability during inspections
An SDEA reduces these risks by establishing agreed procedures for the exchange of safety information and defining which organisation is responsible for specific pharmacovigilance activities.
The agreement therefore functions as a governance mechanism rather than merely a contractual formality.
Situations Requiring an SDEA
The need for an SDEA is determined by operational responsibilities rather than organisational type.
Common examples include:
Licensing Arrangements
Licensors and licensees frequently share responsibilities relating to safety monitoring, regulatory reporting and signal communication. An SDEA helps define how information will be exchanged between the parties.
Co-Marketing and Co-Promotion Agreements
Where multiple companies market the same product, safety information may be received independently by different organisations. Effective exchange mechanisms are required to ensure complete safety surveillance.
Distribution Agreements
Distributors may receive adverse events, product complaints or medical information that requires pharmacovigilance assessment.
Contract Research Organisations
Clinical and post-authorisation activities performed by CROs often generate safety information requiring transfer to the sponsor or marketing authorisation holder.
Pharmacovigilance Service Providers
Vendors performing case processing, literature screening, aggregate reporting or signal management activities generally require clearly documented pharmacovigilance responsibilities.
Core Elements of an SDEA
A well-designed SDEA should provide sufficient detail to support operational compliance while remaining clear and maintainable.
Scope
The agreement should define:
- Products covered
- Territories covered
- Parties included
- Activities within scope
Clearly defining scope helps prevent uncertainty regarding responsibilities.
Responsibilities
This section allocates pharmacovigilance obligations between parties.
Examples include:
- Case intake
- Follow-up activities
- Medical review
- Regulatory submissions
- Literature monitoring
- Signal communication
- Risk management activities
Responsibility allocation should be unambiguous.
Safety Reporting Timelines
One of the most critical sections of any SDEA concerns reporting timelines.
The agreement should specify timelines for:
- Initial transmission of safety information
- Follow-up information exchange
- Escalation of significant safety concerns
- Periodic reconciliations
These timelines must support applicable regulatory reporting requirements.
Communication Pathways
The agreement should describe how information is exchanged, including:
- Contact points
- Functional mailboxes
- Escalation pathways
- Backup arrangements
- Business continuity considerations
Reconciliation Processes
Reconciliation activities help identify discrepancies between databases, case inventories and partner records.
Regular reconciliation is commonly expected where large volumes of safety data are exchanged.
The Relationship Between SDEAs and the Pharmacovigilance System
An SDEA should not be viewed in isolation.
The agreement forms part of the wider pharmacovigilance system and should align with:
- Standard Operating Procedures
- Pharmacovigilance System Master File
- Quality management processes
- Vendor oversight activities
- Compliance monitoring programmes
Inconsistencies between these elements frequently attract regulatory attention.
For example, if a PSMF describes one reporting pathway while an SDEA describes another, inspectors may question whether the pharmacovigilance system is adequately controlled.
QPPV Oversight of SDEAs
The QPPV is not necessarily responsible for drafting or maintaining every agreement. However, regulators generally expect the QPPV to understand how safety information enters and moves through the pharmacovigilance system.
This includes awareness of:
- Key partner arrangements
- Safety reporting pathways
- Escalation mechanisms
- Outsourced pharmacovigilance activities
- Significant compliance risks
An effective oversight model ensures that the QPPV can assess whether contractual arrangements remain appropriate and whether operational performance aligns with documented expectations.
Inspection Perspective
During pharmacovigilance inspections, inspectors frequently review SDEAs when evaluating outsourced activities or partner arrangements.
Inspection activities may include:
- Reviewing agreement provisions
- Assessing reporting timelines
- Verifying reconciliation activities
- Comparing operational practice against documented requirements
- Evaluating governance arrangements
Inspectors are generally interested in whether the agreement functions effectively in practice rather than whether it merely exists.
Evidence of implementation is often as important as the agreement itself.
Common Inspection Findings
Observed deficiencies frequently include:
- Missing agreements
- Outdated agreements
- Incomplete responsibility definitions
- Reporting timelines incompatible with regulatory requirements
- Missing reconciliation processes
- Failure to update agreements following organisational changes
- Inadequate oversight of partner compliance
Many findings arise because agreements are treated as static documents rather than actively governed components of the pharmacovigilance system.
Practical Considerations for Maintaining SDEAs
Effective management typically includes:
- Central agreement inventories
- Defined ownership responsibilities
- Periodic review cycles
- Change-control procedures
- Compliance monitoring
- Performance metrics
- Governance meetings
These activities help ensure that agreements remain aligned with operational reality and regulatory expectations.
Frequently Asked Questions
Is an SDEA legally required?
Requirements depend on the arrangement and jurisdiction. However, pharmacovigilance responsibilities should be clearly documented whenever safety information may be exchanged between organisations.
Does every vendor require an SDEA?
Not necessarily. The determining factor is whether the vendor performs activities that involve pharmacovigilance responsibilities or access to safety information.
Are SDEAs reviewed during inspections?
Yes. They are commonly reviewed during inspections involving outsourced activities, licensing arrangements and partner oversight.
How often should an SDEA be reviewed?
Review frequency varies, but agreements should be reassessed whenever significant organisational, product or process changes occur.
References
- EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
- EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
- EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
- Directive 2001/83/EC, as amended.
- Regulation (EC) No 726/2004, as amended.
- ICH E2D Post-Approval Safety Data Management.
- MHRA Good Pharmacovigilance Practices Guidance.
- FDA Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.